Evidence map›Paper›PMID 37548850›Full record

ArticleJournal of neuro-oncology2023

First in-human intrathecal delivery of bevacizumab for leptomeningeal spread from recurrent glioblastoma: rationale for a dose escalation trial.

Matthew Holdaway, Faina Ablyazova, Shayan Huda, Randy S D'Amico, Tamika Wong, Dana Shani, Netanel Ben-Shalom, John A Boockvar

Registry-linked trialAbstract readCase Reports
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01269853 (Phase I/II Trial Of Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01269853 phase1 / phase2recruitingnot on this map

Phase I/II Trial Of Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab (Avastin) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma.

TypeinterventionalSponsorNorthwell HealthRan2010 to 2029Enrolled54ConditionsGlioblastoma Multiforme, Anaplastic AstrocytomaArmsBevacizumab
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Matthew HoldawayDepartment of Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Lenox Hill Hospital, 130 East 77th Street, New York, NY, 10065, USA. holdawm@amc.edu.
Faina AblyazovaDepartment of Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Lenox Hill Hospital, 130 East 77th Street, New York, NY, 10065, USA.
Shayan HudaCUNY School of Medicine, New York City, NY, USA.
Randy S D'AmicoDepartment of Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Lenox Hill Hospital, 130 East 77th Street, New York, NY, 10065, USA.
Tamika WongDepartment of Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Lenox Hill Hospital, 130 East 77th Street, New York, NY, 10065, USA.
Dana ShaniDepartment of Hematology, Medical Oncology, Internal Medicine, Lenox Hill Hospital, New York City, NY, USA.
Netanel Ben-ShalomDepartment of Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Lenox Hill Hospital, 130 East 77th Street, New York, NY, 10065, USA.
John A BoockvarDepartment of Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Lenox Hill Hospital, 130 East 77th Street, New York, NY, 10065, USA.
Lenox Hill Hospital · USDonald & Barbara Zucker School of Medicine at Hofstra/Northwell · USCUNY School of Law · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo outline the dose rationale for the first in-human intrathecal delivery of bevacizumab for LMS of GBM.

methodsA 19-year-old female patient presented to Lenox Hill Hospital following thalamic GBM recurrence. She subsequently underwent two infusions of intra-arterial BEV (NCT01269853) and experienced a period of relative disease stability until progression in 2022. One month later, MRI disclosed diffuse enhancement representative of LMS of GBM. The patient subsequently underwent five cycles of IT BEV in mid-2022 (IND 162119). Doses of 25 mg, 37.5 mg, 50 mg, 50 mg, and 37.8 mg were delivered at two-week intervals between doses 1-4. The final 37.8 mg dose was given one day following her fourth dose, given that the patient was to be discharged, traveled several hours to our center, and was tolerating therapy well. Dosage was decreased due to the short interval between the final two treatments. Shortly after IT BEV completion, she received a third dose of IA BEV.

resultsOur patient did not show any signs of serious adverse effects or dose limiting toxicities following any of the treatments. It is difficult to determine PFS due to the rapid progression associated with LMS of GBM and rapid timeframe of treatment.

conclusionLMS continues to be a devastating progression in many types of cancer, including GBM, and novel ways to deliver therapeutics may offer patients symptomatic and therapeutic benefits.

Indexed as

Brain NeoplasmsGlioblastomaAdultAntineoplastic Combined Chemotherapy ProtocolsBevacizumabFemaleHumansNeoplasm Recurrence, LocalYoung AdultBevacizumabBevacizumabGlioblastomaIntrathecalLeptomeningeal metastasis

Identifiers

PMID37548850
OpenAlexW4385620652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.